MaaT Pharma Randomises first patient in MaaT033 phase 2 trial in NSCLC

MaaT announced that the first patient has been randomised in the investigator sponsored multicenter phase 2 (IMMUNOLIFE) trial evaluating MaaT033 (microbiome therapy, oral capsule) in combination with cemiplimab (anti PD-1 antibody) in patients with advanced non-small cell lung cancer (NSCLC) who have developed resistance to PD-1/PD-L1 blockade following antibiotic (ATB) exposure and who present ATB-induced gut dysbiosis. Primary results after 1-year follow-up post-treatment could be expected in late 2030, while an interim futility analysis is expected around 1H27, after the 81st randomised patient. € 15 TP and BUY maintained.